Group by Gene: Include preclinical: Immunotherapy Chemotherapy Other RAR/RXR Tyrosine Kinase Inhibitors FGF Epigenetics Wnt Signaling Inhibitors Kinase Inhibitors PI3 Kinase Inhibitors DNA | Thymidylate synthase inhibitor 5-fluorouracil | Multi-tyrosine kinase inhibitor anlotinib | TLR7 agonist, TLR8 agonist imiquimod | Retinoic acid receptor agonist, Telomerase inhibitor, Cytotoxic T lymphocyte stimulant tretinoin | β-catenin inhibitor, CBP inhibitor, Multi-tyrosine kinase inhibitor, Microtubule inhibitor anlotinib + eribulin mesylate | Notch inhibitor, Notch-3 receptor inhibitor, Notch-2 receptor inhibitor, Notch-4 receptor inhibitor, γ-secretase inhibitor AL101 | FGFR2 inhibitor, FGFR inhibitor, VEGFR inhibitor, FGFR1 inhibitor, RET inhibitor, FGFR3 inhibitor, FGFR4 inhibitor, c-KIT inhibitor, γ-secretase inhibitor, PDGFR α antagonist lenvatinib + erdafitinib + γ-secretase inhibitor | ATR inhibitor M6620 | DNA replication inhibitor, AXL-targeted antibody-drug conjugate ADCT-601 | PI3K inhibitor PI3K inhibitor |
---|---|---|---|---|---|---|---|---|---|---|
No biomarker | ||||||||||
BCOR F1106Tfs*5 | ||||||||||
BCOR L1524Hfs*8 | ||||||||||
MYB-NFIB fusion + BCOR F1106Tfs*5 + BCOR L1524Hfs*8 | ||||||||||
MYB underexpression | ||||||||||
NOTCH1 mutation | ||||||||||
NOTCH1 positive + FGFR2 mutation | ||||||||||
NOTCH mutation | ||||||||||
MYB-NFIB fusion | ||||||||||
PIK3CA mutation | ||||||||||
MYB fusion + PIK3CA mutation | ||||||||||
AXL overexpression |